LIVING LONGER WITH ADVANCED
LUNG CANCER IS POSSIBLE

After chemotherapy

KEYTRUDA WITH CHEMOTHERAPY HELPED PATIENTS LIVE LONGER COMPARED TO CHEMOTHERAPY ALONE

A clinical trial compared patients with advanced squamous, non–small cell lung cancer (NSCLC) who received KEYTRUDA in combination with chemotherapy (carboplatin and paclitaxel/nab‑paclitaxel) with those who received chemotherapy alone. All patients in the trial had no previous drug treatment. 278 patients received 200 mg of KEYTRUDA every 3 weeks with chemotherapy for 4 cycles, followed by KEYTRUDA alone, while 281 patients received chemotherapy alone for 4 cycles.

HELPED PATIENTS
LIVE LONGER

More patients treated with KEYTRUDA and chemotherapy were alive at the time of follow-up compared to patients treated with chemotherapy alone.

69%

193 out of 278
patients were
alive

57%

161 out of 281
patients were
alive

KEYTRUDA with CHEMOTHERAPY
(carboplatin and paclitaxel/
nab‑paclitaxel
)

CHEMOTHERAPY
(carboplatin and paclitaxel/
nab‑paclitaxel
)

MORE PATIENTS HAD
TUMORS SHRINK

58%

59 out of 101
patients had their
tumors shrink

35%

36 out of 103
patients had their
tumors shrink

KEYTRUDA with CHEMOTHERAPY
(carboplatin and paclitaxel/
nab‑paclitaxel
)

CHEMOTHERAPY
(carboplatin and paclitaxel/
nab‑paclitaxel
)

KEYTRUDA® (pembrolizumab) With Chemotherapy Reduced the Risk of Squamous Lung Cancer Disease Progression by 44%

KEYTRUDA REDUCED THE RISK OF DISEASE PROGRESSION BY 44%

KEYTRUDA with chemotherapy reduced the risk of cancer spreading, growing, or getting worse by 44% compared with chemotherapy alone.

Half of the patients receiving KEYTRUDA with chemotherapy were alive without their cancer spreading, growing, or getting worse at 6.4 months, compared with 4.8 months for patients treated with chemotherapy alone.

After chemotherapy
See full menu for KEYTRUDA

 

KEYTRUDA is a prescription medicine used to treat a kind of lung cancer called non–small cell lung cancer (NSCLC).

KEYTRUDA may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “nonsquamous” and your tumor does not have an abnormal “EGFR” or “ALK” gene.

KEYTRUDA may be used with the chemotherapy medicines carboplatin and either paclitaxel or nab‑paclitaxel as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called "squamous."

KEYTRUDA may be used alone as your first treatment when your lung cancer has spread (advanced NSCLC) and tests positive for “PD‑L1and your tumor does not have an abnormal “EGFR” or “ALK” gene.

KEYTRUDA may also be used alone for advanced NSCLC if you have tried chemotherapy that contains platinum and it did not work or is no longer working and your lung cancer tests positive for “PD‑L1and, if your tumor has an abnormal “EGFR” or “ALK” gene, you have also received an “EGFR” or “ALK” inhibitor medicine that did not work or is no longer working.

PD‑L1 = programmed death ligand 1; EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase.

KEYTRUDA is a prescription medicine used to treat a kind of lung cancer called non–small cell lung cancer (NSCLC). KEYTRUDA may be used with the chemotherapy medicines pemetrexed and carboplatin as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type of lung cancer called “nonsquamous.”

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma.
KEYTRUDA may be used when your melanoma has spread or cannot be removed by surgery (advanced melanoma).

KEYTRUDA is a prescription medicine used to treat a kind of bladder and urinary tract cancer called urothelial carcinoma. KEYTRUDA may be used when your bladder or urinary tract cancer has spread or cannot be removed by surgery (advanced urothelial cancer) and you have received chemotherapy that contains platinum, and it did not work or is no longer working.

KEYTRUDA is a prescription medicine used to treat a kind of bladder and urinary tract cancer called urothelial carcinoma. KEYTRUDA may be used when your bladder or urinary tract cancer has spread or cannot be removed by surgery (advanced urothelial cancer) and you are not able to receive chemotherapy that contains a medicine called cisplatin and your tumor tests positive for PD‑L1 or you are not able to receive a medicine called cisplatin or carboplatin.

KEYTRUDA is a prescription medicine used to treat a kind of bladder and urinary tract cancer called urothelial carcinoma. KEYTRUDA may be used when your bladder or urinary tract cancer:

  • has spread or cannot be removed by surgery (advanced urothelial cancer) and,
  • you are not able to receive chemotherapy that contains a medicine called cisplatin and your tumor tests positive for PD-L1, or
  • you are not able to receive a medicine called cisplatin or carboplatin, or
  • you have received chemotherapy that contains platinum, and it did not work or is no longer working.

KEYTRUDA is a prescription medicine used to treat a kind of cancer called head and neck squamous cell cancer (HNSCC). KEYTRUDA may be used when your HNSCC has returned or spread and you have received chemotherapy that contains platinum, and it did not work or is no longer working.

KEYTRUDA is a prescription medicine used to treat a kind of cancer called classical Hodgkin lymphoma (cHL). KEYTRUDA may be used for cHL in adults and children when you have tried a treatment and it did not work or when your cHL has returned after you received 3 or more types of treatment.

KEYTRUDA is a prescription medicine used to treat a kind of cancer called cervical cancer that tests positive for “PD-L1.” KEYTRUDA may be used when your cervical cancer has returned, or has spread or cannot be removed by surgery (advanced cervical cancer), and you have received chemotherapy, and it did not work or is no longer working.

KEYTRUDA is a prescription medicine used to treat a kind of liver cancer called hepatocellular carcinoma. KEYTRUDA may be used after you have received the medicine sorafenib.

KEYTRUDA is a prescription medicine used to treat a kind of stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that tests positive for “PD‑L1.” KEYTRUDA may be used when your stomach cancer:

  • has returned or spread (advanced gastric cancer), and
  • you have received 2 or more types of chemotherapy including fluoropyrimidine and chemotherapy that contains platinum, and it did not work or is no longer working, and
  • if your tumor has an abnormal “HER2/neu” gene, you also received a HER2/neu‑targeted medicine and it did not work or is no longer working.

PD‑L1 = programmed death ligand 1; HER2/neu = human epidermal growth factor receptor 2.

KEYTRUDA is a prescription medicine used to treat a kind of cancer that is shown by a laboratory test to be a microsatellite instability-high (MSI‑H) or a mismatch repair deficient (dMMR) solid tumor. KEYTRUDA may be used in adults and children to treat:

  • cancer that has spread or cannot be removed by surgery (advanced cancer), and
  • has progressed following treatment, and you have no satisfactory treatment options, or
  • you have colon or rectal cancer, and you have received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan but it did not work or is no longer working.

It is not known if KEYTRUDA is safe and effective in children with MSI-H cancers of the brain or spinal cord (central nervous system cancers).

KEYTRUDA is a prescription medicine used to treat a kind of cancer called primary mediastinal B-cell lymphoma (PMBCL). KEYTRUDA may be used for PMBCL in adults and children when you have tried a treatment and it did not work or your PMBCL has returned after you received 2 or more types of treatment.

KEYTRUDA is a prescription medicine used to treat:

  • a kind of skin cancer called melanoma. It may be used when your melanoma has spread or cannot be removed by surgery (advanced melanoma).
  • a kind of lung cancer called non–small cell lung cancer (NSCLC).
    • It may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “nonsquamousand your tumor does not have an abnormal “EGFR” or “ALK” gene.
    • It may be used with the chemotherapy medicines carboplatin and either paclitaxel or nab-paclitaxel as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “squamous”.
    • It may be used alone as your first treatment when your lung cancer has spread (advanced NSCLC) and tests positive for “PD‑L1and your tumor does not have an abnormal “EGFR” or “ALK” gene.
    • It may also be used alone for advanced NSCLC if you have tried chemotherapy that contains platinum and it did not work or is no longer working and your lung cancer tests positive for “PD‑L1” and, if your tumor has an abnormal “EGFR” or “ALK” gene, you have also received an “EGFR” or “ALK” inhibitor medicine that did not work or is no longer working.
  • a kind of cancer called head and neck squamous cell cancer (HNSCC). It may be used when your HNSCC has returned or spread and you have received chemotherapy that contains platinum and it did not work or is no longer working.
  • a kind of cancer called classical Hodgkin lymphoma (cHL). It may be used for cHL in adults and children when you have tried a treatment and it did not work or when your cHL has returned after you received 3 or more types of treatment.
  • a kind of cancer called primary mediastinal B-cell lymphoma (PMBCL). It may be used for PMBCL in adults and children when you have tried a treatment and it did not work or your PMBCL has returned after you received 2 or more types of treatment.
  • a kind of bladder and urinary tract cancer called urothelial carcinoma. It may be used when your bladder or urinary tract cancer has spread or cannot be removed by surgery (advanced urothelial cancer) and you are not able to receive chemotherapy that contains a medicine called cisplatin, and your tumor tests positive for PD‑L1, or you are not able to receive a medicine called cisplatin or carboplatin, or you have received chemotherapy that contains platinum, and it did not work or is no longer working.
  • a kind of cancer that is shown by a laboratory test to be a microsatellite instability-high (MSI‑H) or a mismatch repair deficient (dMMR) solid tumor. It may be used in adults and children to treat:
    • cancer that has spread or cannot be removed by surgery (advanced cancer), and
    • has progressed following treatment, and you have no satisfactory treatment options, or
    • you have colon or rectal cancer, and you have received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan but it did not work or is no longer working.
  • It is not known if KEYTRUDA is safe and effective in children with MSI-H cancers of the brain or spinal cord (central nervous system cancers).
  • a kind of stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that tests positive for “PD‑L1.” It may be used when your stomach cancer:
    • has returned or spread (advanced gastric cancer), and
    • you have received 2 or more types of chemotherapy including fluoropyrimidine and chemotherapy that contains platinum, and it did not work or is no longer working, and
    • if your tumor has an abnormal “HER2/neu” gene, you also received a HER2/neu‑targeted medicine and it did not work or is no longer working.
  • a kind of cancer called cervical cancer that tests positive for “PD-L1.” It may be used when your cervical cancer has returned, or has spread or cannot be removed by surgery (advanced cervical cancer), and you have received chemotherapy, and it did not work or is no longer working.
  • a kind of liver cancer called hepatocellular carcinoma. It may be used after you have received the medicine sorafenib.

PD‑L1 = programmed death ligand 1;
EGFR = epidermal growth factor receptor;
ALK = anaplastic lymphoma kinase;
HER2/neu = human epidermal growth factor receptor 2.


 
Important Safety Information About KEYTRUDA® (pembrolizumab)

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen any time during treatment or even after your treatment has ended.

Call or see your doctor right away if you develop any symptoms of the following problems or these symptoms get worse:

Lung problems (pneumonitis). Symptoms of pneumonitis may include shortness of breath, chest pain, or new or worse cough.

Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include diarrhea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems (hepatitis). Signs and symptoms of hepatitis may include yellowing of your skin or the whites of your eyes, nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine, feeling less hungry than usual, or bleeding or bruising more easily than normal.

Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include rapid heartbeat, weight loss or weight gain, increased sweating, feeling more hungry or thirsty, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, muscle aches, dizziness or fainting, or headaches that will not go away or unusual headache.

Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include change in the amount or color of your urine.

Skin problems. Signs of skin problems may include rash, itching, blisters, peeling or skin sores, or painful sores or ulcers in your mouth or in your nose, throat, or genital area.

Problems in other organs. Signs and symptoms of these problems may include changes in eyesight; severe or persistent muscle or joint pains; severe muscle weakness; low red blood cells (anemia); swollen lymph nodes, rash or tender lumps on skin, cough, shortness of breath, vision changes, or eye pain (sarcoidosis); confusion, fever, muscle weakness, balance problems, nausea, vomiting, stiff neck, memory problems, or seizures (encephalitis); and shortness of breath, irregular heartbeat, feeling tired, or chest pain (myocarditis).

Infusion (IV) reactions that can sometimes be severe and life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, shortness of breath or wheezing, itching or rash, flushing, dizziness, fever, or feeling like passing out.

Rejection of a transplanted organ. People who have had an organ transplant may have an increased risk of organ transplant rejection if they are treated with KEYTRUDA.

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your doctor will monitor you for the following signs and symptoms: skin rash, liver inflammation, abdominal pain, and diarrhea.

Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines. Your doctor may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Before you receive KEYTRUDA, tell your doctor if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or plan to have or have had a bone marrow (stem cell) transplant that used donor stem cells (allogeneic); have lung or breathing problems; have liver problems; or have any other medical problems.

If you are pregnant or plan to become pregnant, tell your doctor. KEYTRUDA can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during treatment and for at least 4 months after the final dose of KEYTRUDA. Tell your doctor right away if you become pregnant during treatment with KEYTRUDA.

If you are breastfeeding or plan to breastfeed, tell your doctor. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Common side effects of KEYTRUDA include feeling tired; pain, including pain in muscles, bones, or joints and stomach area (abdominal) pain; decreased appetite; itching; diarrhea; nausea; rash; fever; cough; shortness of breath; and constipation.

Common side effects of KEYTRUDA when given with certain chemotherapy medicines include: feeling tired or weak, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, trouble breathing, fever, hair loss, and inflammation of the nerves that may cause pain, weakness, and paralysis in the arms and legs.

In children, feeling tired, vomiting and stomach-area (abdominal) pain, and increased levels of liver enzymes and decreased levels of salt (sodium) in the blood are more common than in adults.

These are not all the possible side effects of KEYTRUDA. Tell your doctor if you have any side effect that bothers you or that does not go away. For more information, ask your doctor or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

Please read the accompanying Medication Guide for KEYTRUDA and discuss it with your doctor. The physician Prescribing Information also is available.

 Learn about KEYTRUDA for other types of cancers